Ascendis Pharma Announces Results of Study at ENDO 2019 Evaluating Impact of Hypoparathyroidism on Patient Quality-of-Life
March 25, 2019 14:00 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, March 25, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address unmet medical...
Ascendis Pharma Announces Phase 3 heiGHt Trial Demonstrated Superior Efficacy and Comparable Safety and Tolerability of TransCon™ hGH to a Daily Growth Hormone
March 24, 2019 12:45 ET
|
Ascendis Pharma A/S
- Oral presentation of results in pediatric growth hormone deficiency on behalf of investigators at ENDO 2019 - - Patient group acknowledges importance of once-weekly therapy to address overall...
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
March 05, 2019 20:07 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, March 05, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransConTM technology to address unmet medical...
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
March 04, 2019 16:01 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, March 04, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address unmet medical...
Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone Deficiency
March 04, 2019 06:30 ET
|
Ascendis Pharma A/S
- TransCon hGH demonstrated comparable safety and tolerability to a daily hGH - - Potential once-weekly treatment option to overcome long-standing challenges with administration of daily hGH - -...
Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon CNP as Treatment for Achondroplasia
February 28, 2019 20:20 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet...
Ascendis Pharma Initiates Global Phase 2 Trial for TransCon PTH in Adult Subjects with Hypoparathyroidism
February 11, 2019 17:27 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet...
Ascendis Pharma A/S Introduces Vision 3x3: A Strategic Roadmap Through 2025 to Achieve Sustainable Growth Using Multiple Approaches
January 07, 2019 09:00 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address significant...
Ascendis Pharma A/S Announces Participation in 37th Annual J.P. Morgan Healthcare Conference
December 21, 2018 16:01 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, Dec. 21, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet...
Ascendis Pharma A/S Reports Third Quarter 2018 Financial Results
November 28, 2018 16:05 ET
|
Ascendis Pharma A/S
- TransCon CNP preliminary phase 1 data support target product profile and further validates TransCon™ technology - - Diversified pipeline with three independent, clinically-validated rare disease...